Site-directed modification of FVIII

US7632921B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Clark Pan · Sudbury, US
• John E. Murphy · Mobile, US
• Baisong Mei · Newton, US
• Jonathan S. Strauss · Los Angeles, US
• Hendri Tjandra · Union City, US
• Jianmin Chen · New York, US
• Thomas Barnett · East Haven, US
• Liang Tang · Sunnyvale, US
• Deqian Wang · Concord, US

Key dates

• Filing date: Nov 14, 2005
• Grant date: Dec 15, 2009
• Expiry date: Dec 22, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.